New Malaria Test, illumigene® Malaria, Sets a New Gold Standard for Diagnosis
Despite a 60% decline in malaria deaths since 2000, because of better prevention and increased control measures, malaria is still one of the top three killers of children worldwide claiming one life every minute of every day. Malaria is no longer only a disease of sub-Saharan Africa and southern
“illumigene Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria. Earlier diagnosis enables the correct treatment to be prescribed which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. Because of submicroscopic parasitemia carriage among the populations, a robust, sensitive and field community-deployable screening tool is needed to track the malaria reservoir in pre-elimination regions. illumigene Malaria shows this capacity,” said Professor Daouda NDIAYE,
“Patient care is central to Meridian’s work and we consider the needs of all those involved in diagnosis when developing our products. Malaria remains one of the most dangerous diseases in the world both in endemic and increasingly non-endemic countries. illumigene Malaria delivers a high level of sensitivity combined with a quick turnaround time and simple procedure, a combination of attributes that have been lacking in this disease area. Malaria is the tenth assay now available on our illumigene platform that is in use in nearly 1,500 institutions around the world. We are proud to be able to join the fight against Malaria with our flagship illumigene molecular technology.” said
Notes to Editors:
- Professor Ndiaye is Professor of Parasitology and Mycology and Director of the
Senegal African Centre for Excellence on Genomic and Infectious Diseases, based at the University Cheikh Anta Diop, Senegal
- Professor Ndiaye gained his PhD from
Harvard Universityand is currently a visiting scientist at the Harvard TH Chan School of Public Health, Department of Immunology and Infectious Diseases
Daouda Ndiayewill be available for interview upon request.
About illumigene® Malaria & LAMP Technology
- illumigene Malaria is a diagnostic test for malaria developed by
Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the Malaria parasite
- LAMP technology is isothermal and so can be used at room temperature without the need to heat reagents or the material being tested, unlike the rapid diagnostic tests currently used in Malaria which use polymerase chain reaction (PCR) technology. illumigene Malaria does not require refrigeration.
- Illumigene technology is simple, accurate and easy to use which means that no specialist technical expertise is needed to use the test. Results are available in under an hour.
- LAMP based illumigene tests are already used to diagnose infectious diseases including C. difficile, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
- Illumigene tests have been approved and used in other diseases for over 5 years.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For news coverage on product information regarding illumigene® Malaria including interview requests and images (photography of Professor Ndiaye’s
UKand pan-European: Sarah Herbert, Sarah.Herbert@mslgroup.com on +44 203 219 8708
France: Barbara Joly– Barbara.Joly@mslfrance.com on +33 6 61 19 97 96
Spain: Lucia Sixto- firstname.lastname@example.org on +34 93 635 05 00
Italy: Antonella Di-Fatta- email@example.com on +39 33 47 15 13 18
Saudi Arabia: Nahed Ashour- Nahed.firstname.lastname@example.org on +971 50 820 8100
John A. Kraeutler, Chief Executive Officer